Described herein are compositions and methods for hormone replacement therapy that address the shortcomings of the existing methods. Described herein are pharmaceutically effective partial agonistic antiprogestins. The combined application of estrogens (such as estradiol, estriol and conjugated estrogens) and the disclosed partial agonistic antiprogestins can be used in hormone replacement therapy.

Described herein are compositions and methods for hormone replacement therapy that address the shortcomings of the existing methods. Described herein are pharmaceutically effective partial agonistic antiprogestins. The combined application of estrogens (such as estradiol, estriol and conjugated estrogens) and the disclosed partial agonistic antiprogestins can be used in hormone replacement therapy.

The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.

The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.

##STR00001##

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.

##STR00001##

An anti-aging composition comprising: pinebark extract, polypodium leucotomos, ashwagandha extract, dehydroepiandrosterone, white tea extract, alpha lipoic acid, vitamin K2, bioactive silicon, hyaluronic acid, trimethylglycine, and optionally, piperine, green tea extract, folic acid, vitamin C, camu camu, and blueberry extract.

An anti-aging composition comprising: pinebark extract, polypodium leucotomos, ashwagandha extract, dehydroepiandrosterone, white tea extract, alpha lipoic acid, vitamin K2, bioactive silicon, hyaluronic acid, trimethylglycine, and optionally, piperine, green tea extract, folic acid, vitamin C, camu camu, and blueberry extract.

An anti-aging composition comprising: pinebark extract, polypodium leucotomos, ashwagandha extract, dehydroepiandrosterone, white tea extract, alpha lipoic acid, vitamin K2, bioactive silicon, hyaluronic acid, trimethylglycine, and optionally, piperine, green tea extract, folic acid, vitamin C, camu camu, and blueberry extract.

The present invention provides for an antiviral compound and analogues thereof for treatment or prevention of Flavivirus Dengue/Zika infections. In general the antiviral compound includes Eplerenone [pregn-4-ene-7, 21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo, γ-lactone, methyl ester (7α, 11α, 17α)] and its metabolites. Methods presented include treating Flavivirus infections, such as Zika virus, dengue virus, yellow fever virus and tick-borne encephalitis virus and Japanese encephalitis virus by administering the compound Eplerenone in therapeutically effective amounts and specific formulations as disclosed.